Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Med Care. 2018 Jan;56(1):69–77. doi: 10.1097/MLR.0000000000000840

Table 2.

Factors associated with faster speed of adoption across practices

Cancer type and practice characteristics Hazard ratio (95% CI) P value
Cancer type
 Colorectal cancer Reference
 Lung cancer .076 (.065 to .088) <.001
 Breast cancer .032 (.026 to .038) <.001
Practice type, N (%)
 Independent Reference
 Hospital-owned (non-academic) .89 (.67 to 1.17) .39
 Academic .48 (.33 to .68) <.001
Number of oncologists in practice (for each additional doctor above mean) 1.05 (1.04 to 1.06) <.001
Ratio of oncologists to all physicians (for each 10 percentage point increase above mean) 1.03 (1.01 to 1.05) 0.004
Proportion of individuals treated in practice living in high-poverty areas (for each 10 percentage point increase above the mean) .98 (.93 to 1.03) .48
*

Using Frailty models to estimate time to adoption in the 1128 practices with at least one patient with colorectal, lung, and breast cancer in 2005. Models adjusted for all practice characteristics in the table. Kendall’s Tau—which estimates the correlation between use of bevacizumab for different cancer types within the same practice—was .29, suggesting moderate correlation.